or Try an Advanced Search...

    Technical Analysis for SLRX - Salarius Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 1.48 5.71% 0.08
    SLRX closed down 0.71 percent on Wednesday, November 20, 2024, on 11 percent of normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Up
    Historical SLRX trend table...
    Date Alert Name Type % Chg
    Shooting Star Candlestick Bearish 5.71%
    Doji - Bearish? Reversal 5.71%
    Outside Day Range Expansion 5.71%
    Wide Bands Range Expansion 5.71%
    Oversold Stochastic Weakness 5.71%
    Stochastic Buy Signal Bullish 4.96%
    Spinning Top Other 4.96%
    Narrow Range Bar Range Contraction 4.96%
    Inside Day Range Contraction 4.96%
    Wide Bands Range Expansion 4.96%
    Older End-of-Day Signals for SLRX ...

       Recent Intraday Alerts

    Alert Time
    10 DMA Support 2 minutes ago
    Up 5% 2 minutes ago
    Rose Above 10 DMA about 3 hours ago
    Up 3% about 3 hours ago
    Up 2% about 3 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    SLRX Chart by TradingView
    Basic chart:

    Profile

    Salarius Pharmaceuticals, Inc. a clinical-stage oncology company, develops therapies for the treatment of patients with various cancers. The company's lead candidate is Seclidemstat, which is in clinical development for the treatment of Ewing sarcoma, as well as advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Cancer Solid Tumors Clinical Development Oncology Breast Cancer Prostate Cancer Ovarian Cancer Treatment Of Breast Cancer Sarcoma Advanced Solid Tumors

    Is SLRX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 15 Salarius: Q3 Earnings Snapshot
    Aug 9 Salarius: Q2 Earnings Snapshot
    Jul 30 (SLRX) - Analyzing Salarius Pharmaceuticals's Short Interest
    Jul 22 Why Tellurian Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket
    Jul 19 Why Intuitive Surgical Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
    Jul 11 Sector Update: Health Care Stocks Rise Late Afternoon
    Jun 12 Salarius Pharmaceuticals to effect 1-for-8 reverse stock split to regain Nasdaq compliance
    Jun 12 Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split
    See more SLRX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 7.272
    52 Week Low 1.26
    Average Volume 403,590
    200-Day Moving Average 2.96
    50-Day Moving Average 1.56
    20-Day Moving Average 1.51
    10-Day Moving Average 1.42
    Average True Range 0.13
    RSI (14) 42.20
    ADX 9.92
    +DI 23.11
    -DI 21.18
    Chandelier Exit (Long, 3 ATRs) 1.64
    Chandelier Exit (Short, 3 ATRs) 1.73
    Upper Bollinger Bands 1.75
    Lower Bollinger Band 1.28
    Percent B (%b) 0.26
    BandWidth 30.88
    MACD Line -0.07
    MACD Signal Line -0.05
    MACD Histogram -0.0129
    Fundamentals Value
    Market Cap 5.51 Million
    Num Shares 3.94 Million
    EPS -6.59
    Price-to-Earnings (P/E) Ratio -0.21
    Price-to-Sales 18.12
    Price-to-Book 0.37
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.56
    Resistance 3 (R3) 1.57 1.53 1.54
    Resistance 2 (R2) 1.53 1.48 1.52 1.53
    Resistance 1 (R1) 1.46 1.46 1.45 1.45 1.52
    Pivot Point 1.42 1.42 1.41 1.41 1.42
    Support 1 (S1) 1.35 1.38 1.35 1.35 1.28
    Support 2 (S2) 1.31 1.35 1.30 1.27
    Support 3 (S3) 1.24 1.31 1.26
    Support 4 (S4) 1.24